How Antitrust Issues Can Surface After a Healthcare Acquisition
As more and more medical practices consolidate, antitrust concerns rise to the surface. Hospital system expansions, private equity investment, and other mergers can trigger regulatory compliance concerns under both federal and state law. Physicians in New York considering a private equity or other sale must understand how antitrust concerns can affect the deal, unwind your transaction, or lead to significant penalties.
The medical transaction attorneys at Daniels, Porco & Lusardi, LLP know how antitrust issues can impact your practice and any healthcare transactions you are considering
Market Power Becomes More Visible After Integration
Many acquisitions appear compliant on paper because the parties underestimate their combined market share. But once the buyer integrates scheduling, referral patterns, payer negotiations, and branding, regulators may view the combined entity as having more market power than originally disclosed.
Post-closing, the following red flags often draw attention:
- A sudden increase in patient volume due to internal referrals
- Consolidation of specialty services within a geographic area
- Reduced availability of competing providers
- Noticeable price increases or payer complaints
- Exclusive contracting that limits patient choice
New York’s Attorney General (NYAG) and the Federal Trade Commission (FTC) both monitor these patterns. Even if a transaction did not require pre-closing notification under the Hart-Scott-Rodino Act, regulators can still challenge it later if competitive harm becomes apparent.
Payer Contracting Raises Red Flags
One of the most common triggers for antitrust scrutiny in New York is how the newly combined practice negotiates with insurers. When a PE-backed platform or large medical group gains leverage, payers may push back.
Issues that often surface include:
- Demands for higher reimbursement rates based on increased market share
- “All-or-nothing” contracting across multiple practice locations
- Steering patients toward affiliated facilities
- Refusing to participate in certain networks unless payers accept new terms
Referral Patterns Shift in Ways That Suggest Anti-Competitive Behavior
After an acquisition, referral patterns often change. Regulators pay close attention to:
- Internalizing referrals to affiliated specialists or facilities
- Reducing referrals to independent competitors
- Incentive structures that reward in-network referrals
- MSO-driven operational policies that limit physician discretion
While some referral consolidation is expected, regulators become concerned when patient choice is restricted or when referral changes appear tied to financial incentives rather than clinical judgment.
In New York, these concerns intersect with CPOM rules. If a non-physician entity influences referral decisions, the issue becomes both an antitrust and CPOM compliance problem.
Exclusive Agreements and Non-Competes
Post-acquisition, many groups implement:
- Exclusive provider agreements
- Non-compete clauses
- Non-solicitation restrictions
- Requirements that physicians practice only within the platform
If a practice uses non-competes to prevent physicians from leaving and competing, regulators may question whether the restrictions harm patient access or artificially inflate prices.
“Roll-Up” Strategies
Private equity roll-ups, where a platform acquires multiple practices in the same specialty, are a major focus of federal and state regulators. Even if each individual acquisition is small, the cumulative effect can create significant market concentration.
In New York, retrospective review often occurs when:
- A platform acquires several practices in the same specialty within a short period
- Competitors complain about shrinking referral networks
- Payers report increased rates or reduced negotiating flexibility
- Patients experience reduced access or longer wait times
Operational Integration Reveals Anti-Competitive Conduct
Sometimes antitrust issues arise not from the acquisition itself, but from how the combined entity operates afterward. Examples include:
- Standardizing prices across formerly independent practices
- Coordinating scheduling or capacity in ways that limit competition
- Sharing competitively sensitive information among affiliated groups
- Implementing MSO policies that restrict physician autonomy
These behaviors can be interpreted as anti-competitive coordination, especially when they affect market pricing or patient access.
Avoid Antitrust Issues by Working with a Skilled Healthcare Transaction Attorney
Antitrust issues can arise quickly if you don’t know what to watch for. In many PE-backed acquisitions, PE firms and physicians fail to account for these important considerations, leading to significant legal issues.
The attorneys at Daniels, Porco & Lusardi, LLP are ready to help. Contact us today for a consultation.